Centessa Pharmaceuticals: forging a new path for pharma R&D
Centessa Pharmaceuticals, a company trying out an unorthodox approach to R&D, rounds up some of its star acquisitions.
Analysis
FDA approves Boehringer’s oral blood thinner Pradaxa for children
Pradaxa, initially authorised in 2010, is the first oral blood thinner approved by the FDA...
Debiopharm and Ubix join forces to develop new anti-cancer modality
The companies are combining their proprietary technologies to develop Antibody Degraducer Conjugates.
Cities are imperceptibly becoming Smart Cities. But what does that actually mean?
The term smart city has evoked various descriptions at some point, but the world’s existing...
Umoja Biopharma raises $210m to advance next-gen cancer immunotherapy technology
The company is building an integrated cellular immunotherapy platform to reprogramme immune cells in vivo.
Aducanumab: Promising Alzheimer’s drug or dangerous precedent?
The FDA has overruled the recommendations of its advisory panel, who were almost unanimously against approving the controversial drug.
Covid and Big Tech are driving Augmented Reality into healthcare
Augmented Reality tech is helping hospitals to deliver better patient care while at the same time cutting down on Covid infection danger, as Giacomo Lee reports.
Gene writing: The future of genetic medicine?
Tessera Therapeutics’ new technology could write therapeutic messages into genomes, treating genetic diseases at their source.
Bacterial “cell factories”: an eco-friendly approach to chemical production
Researchers at the University of Warwick have designed a genetic switch that reroutes bacteria’s chemistry to produce chemicals.
Robots make more business sense with AI – just don’t expect fireworks
Robot use is becoming increasingly practical, which means that such machinery is being increasingly employed – and AI can only make robotics better, as Giacomo Lee finds out.
How is activity in the pharma sector recovering from Covid-19’s impact?
Analysis of jobs, deals, stock prices and financial filings and news sentiments now show pharma to be a relative winner when it comes to Covid-19 recovery.
